Abstract
PurposeThe aim of this study was to explore the prognostic value of total metabolic tumor volume (TMTV) at baseline 18F-FDG PET/CT in patients diagnosed with peripheral T-cell lymphoma (PTCL).Materials and methodsEighty-four newly diagnosed PTCL patients who underwent baseline 18F-FDG PET/CT prior to treatment between March 2009 and January 2019 were enrolled in this retrospective study. The FDG-avid lesions in each patient were segmented using semiautomated software to calculate the maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG) values using the boundaries of voxels presenting with the 41% SUVmax threshold method. Progression-free survival (PFS) and overall survival (OS) were used as end points to evaluate patient prognosis. The log-rank test and Cox regression analyses were used to evaluate PFS and OS.ResultsROC curve analysis indicated an ideal TMTV cut-off value of 228.8 cm3. During the 4–131 months (29.2 ± 28.5 months) follow-up period, high TMTV was significantly associated with worse PFS and OS. TMTV and the international peripheral T-cell lymphoma project score (IPTCLP) were independent predictors of PFS and OS with multivariate analysis. The combination of TMTV and the IPTCLP may provide significantly better risk substratification in PFS and OS of PTCL patients.ConclusionsBoth TMTV and IPTCLP are independent predictors of PTCL patient survival outcomes. Moreover, the combination of TMTV and IPTCLP improved patient risk stratification and may contribute to personalized therapeutic regimens.
Highlights
Peripheral T-cell lymphomas (PTCLs) constitute a heterogeneous and uncommon group of malignancies derived from post-thymic T cells or mature natural killer (NK) cells, representing approximately less than 15% of all nonHodgkin lymphomas [1]
A new score taking age, performance status, and platelet count into consideration as main variables introduced by Vose was presented as the International peripheral T cell lymphoma Project (IPTCLP) in PTCL patients, but the prognostic value has been verified by only a few studies [5,6,7]
Patients Patients recently diagnosed with PTCL who underwent pretreatment whole-body 18F-FDG PET/CT between March 2009 and January 2019 were enrolled in this retrospective study
Summary
Peripheral T-cell lymphomas (PTCLs) constitute a heterogeneous and uncommon group of malignancies derived from post-thymic T cells or mature natural killer (NK) cells, representing approximately less than 15% of all nonHodgkin lymphomas [1]. The nodal lymphoma group, as classified by the World Health Organization, contains four subtypes: peripheral T-cell lymphoma (PTCL) not otherwise specified (PTCL-NOS), angioimmunoblastic. The prognostic index for PTCL (PIT), including 4 clinical characteristics (age, Eastern Cooperative Oncology Group performance status [ECOG PS], serum lactate dehydrogenase [LDH] and bone marrow [BM] involvement) as a basic tool for risk stratification of PTCL, has been widely used in clinical practice [4]. A new score taking age, performance status, and platelet count into consideration as main variables introduced by Vose was presented as the International peripheral T cell lymphoma Project (IPTCLP) in PTCL patients, but the prognostic value has been verified by only a few studies [5,6,7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
